186 related articles for article (PubMed ID: 21239834)
1. Update on iron chelators in thalassemia.
Neufeld EJ
Hematology Am Soc Hematol Educ Program; 2010; 2010():451-5. PubMed ID: 21239834
[TBL] [Abstract][Full Text] [Related]
2. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
[TBL] [Abstract][Full Text] [Related]
3. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
4. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
[TBL] [Abstract][Full Text] [Related]
5. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
6. Real-world use of iron chelators.
Kwiatkowski JL
Hematology Am Soc Hematol Educ Program; 2011; 2011():451-8. PubMed ID: 22160073
[TBL] [Abstract][Full Text] [Related]
7. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
[TBL] [Abstract][Full Text] [Related]
8. Current recommendations for chelation for transfusion-dependent thalassemia.
Kwiatkowski JL
Ann N Y Acad Sci; 2016 Mar; 1368(1):107-14. PubMed ID: 27186943
[TBL] [Abstract][Full Text] [Related]
9. New developments in iron chelators.
Cunningham MJ; Nathan DG
Curr Opin Hematol; 2005 Mar; 12(2):129-34. PubMed ID: 15725903
[TBL] [Abstract][Full Text] [Related]
10. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
11. Iron mobilization using chelation and phlebotomy.
Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
[TBL] [Abstract][Full Text] [Related]
12. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
13. Deferiprone.
Piga A; Roggero S; Salussolia I; Massano D; Serra M; Longo F
Ann N Y Acad Sci; 2010 Aug; 1202():75-8. PubMed ID: 20712776
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy with deferoxamine and deferiprone.
Kattamis A
Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and treatment of transfusional iron overload in children.
Ware HM; Kwiatkowski JL
Pediatr Clin North Am; 2013 Dec; 60(6):1393-406. PubMed ID: 24237978
[TBL] [Abstract][Full Text] [Related]
18. The Egyptian experience with oral iron chelators.
El Beshlawy A
Hematology; 2005; 10 Suppl 1():174-5. PubMed ID: 16188665
[TBL] [Abstract][Full Text] [Related]
19. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
20. Iron chelation therapy for transfusional iron overload: a swift evolution.
Musallam KM; Taher AT
Hemoglobin; 2011; 35(5-6):565-73. PubMed ID: 21910602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
